Research recommendation(s) from an individual piece of guidance
- Guidance:
- Bladder cancer: diagnosis and management
- Date issued:
-
Research recommendations coming out of this guidance
-
What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer?
-
Is primary radical cystectomy more effective than primary intravesical BCG (Bacille Calmette-Guérin) in high risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes?
-
In people with high-risk non-muscle-invasive bladder cancer, are these follow-up regimens equally
effective in terms of identification of progression, cost effectiveness and health-related quality of
life?
- Cystoscopic follow-up at 3, 6, 12, 18, 24, 36 and 48 months, and then annually, interspersed
with non-invasive urinary tests.
- Cystoscopic follow-up at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 months, and then annually
thereafter.
-
In patients with muscle-invasive bladder cancer suitable for radical treatment, does the use of
biomarkers enable patients to select more effective treatment, and improve their outcomes,
compared with treatment selected without biomarkers?
-
Is symptom-based review as effective as scheduled follow-up for people treated with radical
cystectomy or radical radiotherapy for organ-confined, muscle-invasive bladder cancer? Outcomes
of interest are overall survival, health-related quality of life, resource use and cost.